Literature DB >> 18173452

Novel intraoral phenotypes in hyperimmunoglobulin-E syndrome.

D L Domingo1, A F Freeman, J Davis, J M Puck, W Tianxia, S M Holland, T C Hart.   

Abstract

AIM: Hyperimmunoglobulin-E syndrome (HIES) is a primary immunodeficiency characterized by eczema, recurrent skin and lung infections with pneumatocoele formation, and extremely elevated serum immunoglobulin-E. The precise immunologic defect and genetic etiology remain unknown. Non-immunologic findings include characteristic facial features (prominent forehead, fleshy nasal tip, and increased interalar distance); skeletal involvement (pathological fractures, scoliosis, and craniosynostosis); and retention of primary teeth. This study aims to characterize intraoral soft tissue findings in HIES patients.
METHODS: Sixty HIES patients (4-54 years, 27 males, 33 females) received intraoral and radiographic evaluations. Chronological dental development was also assessed.
RESULTS: Lesions of the hard palate and dorsal tongue were found in 55% and 60% of patients, respectively. Palatal lesions ranged from a generalized surface keratosis to a midline sagittal fibrotic bridge. Tongue lesions consisted of multiple fissures and a midline cleft. On the lip and buccal mucosa, keratotic plaques and/or surface fissures were found in 8% and 23% of patients, respectively. Manifested in 76.7% of patients, the intraoral lesions were significantly more prevalent than the characteristic facial traits (P=0.0013).
CONCLUSIONS: Alterations in oral mucosa and gingiva were present in the majority of HIES patients. These novel intraoral findings may facilitate the diagnosis of HIES.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18173452     DOI: 10.1111/j.1601-0825.2007.01363.x

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  14 in total

Review 1.  Hyper-IgE syndrome update.

Authors:  Kathryn J Sowerwine; Steven M Holland; Alexandra F Freeman
Journal:  Ann N Y Acad Sci       Date:  2012-01-23       Impact factor: 5.691

2.  Paucity of genotype-phenotype correlations in STAT3 mutation positive Hyper IgE Syndrome (HIES).

Authors:  Jennifer Heimall; Joie Davis; Pamela A Shaw; Amy P Hsu; Wenjuan Gu; Pam Welch; Steven M Holland; Alexandra F Freeman
Journal:  Clin Immunol       Date:  2011-01-14       Impact factor: 3.969

Review 3.  Host responses to Candida albicans: Th17 cells and mucosal candidiasis.

Authors:  Heather R Conti; Sarah L Gaffen
Journal:  Microbes Infect       Date:  2010-04-08       Impact factor: 2.700

Review 4.  Th17 cells, Job's syndrome and HIV: opportunities for bacterial and fungal infections.

Authors:  Joshua D Milner; Netanya G Sandler; Daniel C Douek
Journal:  Curr Opin HIV AIDS       Date:  2010-03       Impact factor: 4.283

5.  Oral Manifestations of Job's Syndrome in a Paediatric Dental Patient - A Case Report.

Authors:  Jeswin James; Anupam Kumar Thekkeveetil; Kannan Vadakkepurayil
Journal:  J Clin Diagn Res       Date:  2016-11-01

Review 6.  Genetic studies of craniofacial anomalies: clinical implications and applications.

Authors:  T C Hart; P S Hart
Journal:  Orthod Craniofac Res       Date:  2009-08       Impact factor: 1.826

Review 7.  The hyper-IgE syndromes.

Authors:  Alexandra F Freeman; Steven M Holland
Journal:  Immunol Allergy Clin North Am       Date:  2008-05       Impact factor: 3.479

Review 8.  Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes.

Authors:  Alexandra F Freeman; Steven M Holland
Journal:  Pediatr Res       Date:  2009-05       Impact factor: 3.756

9.  Fungal infection of gingiva in a patient with hyperimmunoglobulin-E (Job's) syndrome.

Authors:  D Deepa; K V Arun Kumar; Chander Shekhar Joshi; Sanjeev Kumar; Anita Pandey
Journal:  J Indian Soc Periodontol       Date:  2012-04

Review 10.  An update on the hyper-IgE syndromes.

Authors:  Patrick F K Yong; Alexandra F Freeman; Karin R Engelhardt; Steven Holland; Jennifer M Puck; Bodo Grimbacher
Journal:  Arthritis Res Ther       Date:  2012-11-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.